Randomized controlled trial on timing and number of sampling for bile aspiration cytology

Tsuchiya, Tomonori; Yokoyama, Yukihiro; Igami, Tsuyoshi; Sugawara, Gen; Kato, Kazushige; Shimoyama, Yoshie; Nagino, Masato

doi:10.1002/jhbp.61

Cited by 15 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the use of advanced imaging techniques, diagnosis is uncertain [ 22 ]. Moreover, studies have found that 3–17 % of patients with suspected malignant stenosis were eventually diagnosed with a benign lesion through postoperative histological examination [ 23 , 24 ]. In many cases, diagnosis is based on bile cytology.…”

Section: Discussionmentioning

confidence: 99%

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background Wisteria floribunda agglutinin (WFA)-sialylated mucin core polypeptide 1 (MUC1) was investigated as a new glycoprotein marker for cholangiocarcinoma (CC) using glycoproteomics technologies. In this multicenter study, WFA-sialylated MUC1 levels in serum and bile samples were measured to determine their diagnostic capability in biliary tract carcinoma (BTC) and intrahepatic (Ih) CC.MethodsThe study included 244 patients with BTC, 59 patients with IhCC, 287 patients with benign biliary tract diseases, and 44 control subjects.ResultsSerum WFA-sialylated MUC1 levels were significantly higher in patients with either BTC or IhCC than in control subjects and those with benign biliary tract diseases. Patients with IhCC showed higher WFA-sialylated MUC1 levels than patients with tumors at other sites. No significant differences in WFA-sialylated MUC1 levels were found with regard to cancer stage or tissue type. Receiver operating characteristic curve analysis showed that WFA-sialylated MUC1 was superior to carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for the diagnosis of benign biliary tract diseases, BTC, and IhCC, as well as for stage I and II carcinomas. Significantly higher levels of biliary WFA-sialylated MUC1 were observed in BTC/IhCC than in benign biliary tract diseases. The diagnostic capability of biliary WFA-sialylated MUC1 was also superior to that of CA19-9, and diagnostic sensitivity was higher than that of biliary cytology for BTC/IhCC.ConclusionsWFA-sialylated MUC1 is a useful novel biomarker for BTC/IhCC. In the future, this measurement should be applied in the clinical setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most commonly performed diagnostic method for CCA is biliary cytology, which tests the bile sample from a biliary drainage catheter. However, the sensitivity of biliary cytology is extremely low (20.7%±3.5%) as reported in published study 58. In our meta-analysis of the diagnostic capability of markers for CCA, seven prospective trials12 31-32 34 35 55and a retrospective study9 were eligible for diagnostic analysis that showed that the diagnostic capability of CA19-9 was inferior to other molecules, such as WFA-MUC1.…”

Section: Discussionmentioning

confidence: 78%

Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma

et al. 2019

View full text Add to dashboard Cite

ObjectiveSerum carbohydrate antigen 19–9 (CA19-9) is a widely used tumour marker for cholangiocarcinoma (CCA). However, it is not a necessarily good CCA marker in terms of diagnostic accuracy. The purpose of this study is to evaluate the diagnostic value of Wisteria floribundaagglutinin-sialylated Mucin1 (WFA-MUC1) and the prognostic role of Mucin1 (MUC1) in human CCA.DesignMeta-analysis.Data sourcesStudies published in PubMed, Web of Science, The Cochrane Library and the China National Knowledge Infrastructure up to 11 October 2017.Eligibility criteriaWe included reports assessing the diagnostic capacity of WFA-MUC1 and the prognostic role of MUC1 in CCA. The receiver operating characteristic curve (ROC) of WFA-MUC1 and/or CA19-9 was described, and the HRs including 95% CI and the corresponding p value for MUC1 can be extracted.Data extraction and synthesisTwo independent researchers extracted data and assessed risk of bias. The diagnostic sensitivity and specificity data of WFA-MUC1 were extracted and analysed as bivariate data. Pooled HRs and its 95% CI for MUC1 were calculated with a random-effects meta-analysis model on overall survival of resectable CCA.ResultsSixteen reports were included in this study. The pooled sensitivity and specificity of WFA-MUC1 were 0.76 (95% CI 0.71 to 0.81) and 0.72 (95% CI 0.59 to 0.83) in serum, 0.85 (95% CI 0.81 to 0.89) and 0.72 (95% CI 0.64 to 0.80) in bile and 0.72 (95% CI 0.50 to 0.87) and 0.85 (95% CI 0.70 to 0.93) in tissue, respectively. The summary ROC (SROC) were 0.77 (95% CI 0.73 to 0.81) in serum, 0.88 (95% CI 0.85 to 0.90) in bile and 0.86 (95% CI 0.83 to 0.89) in tissue, respectively. Furthermore, the pooled sensitivity and specificity and the SROC of CA19-9 in serum were 0.67 (95% CI 0.61 to 0.72), 0.86 (95% CI 0.75 to 0.93) and 0.75 (95% CI 0.71 to 0.79), respectively. The pooled HRs for MUC1 was 2.20 (95% CI 1.57 to 3.01) in CCA and 4.17 (95% CI 1.71 to 10.17) in mass-forming intrahepatic CCA.ConclusionsCompared with CA19-9, WFA-MUC1 was shown to possess stronger diagnostic capability. MUC1 could serve as a prognosis factor for poor outcomes of CCA, particularly, mass-forming intrahepatic CCA.

show abstract

“…We recently performed a study to determine the effective sampling number to increase the diagnostic accuracy of biliary cytology. 1 This study demonstrated that the positivity of cytology in a onetime sampling session was only 25.6 %. The cumulative positivity was approximately 50 %, even after 10 sampling patients with benign diseases), and we further confirmed the diagnostic value of the WFA-sialylated MUC1 ELISA system for bile samples.…”

Section: Discussionmentioning

confidence: 95%

“…However, the sensitivity of biliary cytology was unexpectedly low in a previous study. 1 Serum carbohydrate antigen 19-9 (CA19-9) also is a commonly used tumor marker for bile duct cancer. However, the level of CA19-9 may be modified by the presence of biliary stricture or hyperbilirubinemia.…”

mentioning

confidence: 99%

Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Randomized controlled trial on timing and number of sampling for bile aspiration cytology

Abstract: Bile cytology positivity is unlikely to be affected by sample time.

Cited by 15 publications

References 28 publications

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study

Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma

Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer

Contact Info

Product

Resources

About